Yawn, more poorly executed FUD attempts then?Where is the money coming from for MSB's grand commercial plans?
Where is the money coming for any of these small cap innovators? Any bio-tech in pre-commerical activities in the modern era? Do you even know what you are invested in? Evidently not in given your comments on here.
Do you think MSB would be trading $1.20 had it not managed to partner with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) in trials for Ryoncil (remestemcel-L) in SR-aGvHD. Every MSB investor (including me) knows we'd have been stuffed if Silviu had not secured such a great trial partnership, let alone the obvious effects of the Novartis commercial partnership demise.
Partnerships are their survival in bio-tech. Silviu knows that . Killian knows that. Everyone in the bio-tech innovation space gets how all of these companies rely on both trial and commercial partnerships for their continued existence in the onerous world of bio-tech innovation, bar you it seems.
You really need to improve your attempts at FUD on CYP as they are increasingly making yourself look ignorant on CYP, stem-cell and bio-tech investments generally. Mistakes on cash burn rates and trial recruitments, etc, that are all quite contrary to the official ASX releases, would you only learn to read them.
CYP Price at posting:
29.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)